Italfarmaco
BiotechItaly
1
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
5
Indications↗
Distinct diseases across all programs
31
Clinical Trials↗
All sponsored trials (all statuses)
5
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
1 drugs in development
Phase 31
Phase 21
By Therapeutic Area
top 4
Hematology
125%
Rare Disease
125%
Neurology
125%
Musculoskeletal
125%
R&D Momentum
32/100
Pipeline Velocity
0/100
Trial Completion Rate
75/100
Pipeline Concentration
25/100
Pipeline Freshness
50/100
Strategic Signals
- ↗Active in Hematology but thin pipeline — potential licensing opportunity
Activity
Key Events
Mar 8, 2026TrialEPIDYS: Givinostat in Ambulant DMD Patients
May 28, 2025TrialPharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic Function
Jan 2, 2025TrialPharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old
Mar 26, 2024TrialStudy on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Mar 21, 2024FDADuvyzat — DUVYZAT
Feb 19, 2024TrialEfficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
Jul 20, 2023TrialA Multicentre, Prospective, Open-label, Non-comparative Study
Apr 5, 2023TrialMulticenter Prospective Real-world Observational Study to Evaluate the Effectiveness of Phlebotonics, as Conservative Therapy in a Cohort of Patients With Symptomatic Hemorrhoidal Disease (HD) of I, II or III Goligher Grade
4 more events
Mar 21, 2022TrialGivinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)
Mar 21, 2022TrialThe Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)
Mar 21, 2022TrialPerpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity
Apr 13, 2021TrialPlacebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval
Details
Company Info
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Hematology
Musculoskeletal
Rare Disease
Regulatory
Regulatory Timeline
20241 event
FDAMar 21
Duvyzat — DUVYZAT
Application NDA217865 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)